Welcome to OVG
The Oxford Vaccine Group has been at the forefront of vaccine development for 30 years, helping to fight diseases of major global importance through research and education around the world.
What's Happening?
30 Years of OVG
1994 - 2024
Join our celebrations and learn about 30 years of ground-breaking research at OVG
Study Spotlight
| BiVISTA👤 18 to 55 years old 📅 24 to 31 visits over 7 months 💉1 vaccination and 1 challenge 🧬 Could you be a part of the battle against Typhoid and Paratyphoid fever? 🪙 Up to £4585 reimbursement |
Be a Vaccine Hero
Take part in a study
Could you be a Vaccine Hero by taking part in one of our clinical trials? Find out about the trials and studies currently looking for volunteers, as well as what it is like taking part from previous participants
Study - LEGACY02
A study examining lymph node cells to assess how age affects immune responses to a new vaccine.
Study - PCV15-PCV20
A study which will guide decisions on future changes to the routine UK immunisation schedule.
Study - RATIONALE-15
Help us to understand how pneumonia vaccines work!
Research at OVG
Education, Learning and Public Involvement
Latest Publications
⠀⠀⠀⠀⠀
-
A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine
Journal article
Dold C. et al, (2025), Science Translational Medicine, 17
-
Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.
Journal article
Ibarz-Pavon AB. et al, (2025), Vaccine, 56
-
Severe Parvovirus B19-Associated Myocarditis in Children in the Post-COVID-19 Era: A Multicenter Observational Cohort Study.
Journal article
Russell N. et al, (2025), Open Forum Infect Dis, 12
-
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Journal article
Milotay G. et al, (2025), Nature Medicine
Working Together
National Immunisation Schedule Evaluation Consortium II
OVG is proud to lead NISEC II, a collaboration between a network of Academic Clinical Research groups and the UK Health Security Agency.
Immune Memory and Mechanisms of Protection from Vaccines
Oxford is proud to host the IMMPROVE consortium of universities, government, industry and others.
